|
1
|
Santos Freire M, Victor de Oliveira Monteiro A, Moura Martins T, Socorro Silva Lima Duarte M, Carlos Lima A, Luiz Araújo Bentes Leal A, Rodolfo Pereira da Silva F, Fernando Marques Barcellos J. Genetic variations in immune mediators and prostate cancer risk: A field synopsis with Bayesian calculations. Cytokine 2024; 179:156630. [PMID: 38696882 DOI: 10.1016/j.cyto.2024.156630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Revised: 04/01/2024] [Accepted: 04/28/2024] [Indexed: 05/04/2024]
Abstract
OBJECTIVE Our study aimed to revaluate the significant data from meta-analyses on genetic variations in immune mediators and the risk of prostate cancer (PCa) by Bayesian approaches. METHODS We performed a search on the literature before September 5th, 2023, for meta-analytic studies on polymorphisms in immune mediator genes and the risk of PCa. Two Bayesian approaches were used to assess the level of noteworthiness in the meta-analytic data: the False-Positive Rate Probability (FPRP) and the Bayesian False Discovery Probability (BFDP) with a statistical power of 1.2 and 1.5 of Odds Ratio at a prior probability of 10-3 and 10-6. The quality evaluation of studies was performed with the Venice criteria. Gene-gene and protein-protein networks were designed for the genes and products enrolled in the results. RESULTS As results, 18 meta-analyses on 17 polymorphisms in several immune mediator genes were included (IL1B rs16944/rs1143627, IL4 rs2243250/rs2227284/rs2070874, IL6 1800795/rs1800796/rs1800797, IL8 rs4073, IL10 rs1800896/rs1800871/rs1800872, IL18 rs1946518, COX2 rs2745557, TNFA rs361525 and PTGS2 rs20417/689470). The Bayesian calculations showed the rs1143627 and the rs1946518 polymorphisms in IL1B and IL18 genes, respectively, were noteworthy. The Venice criteria showed that only four studies received the highest level of evidence. The gene-gene and protein-protein networks reinforced the findings on IL1B and IL18 genes. CONCLUSION In conclusion, this current Bayesian revaluation showed that the rs1143627 and the rs1946518 polymorphisms in the IL1B and IL18 genes, respectively, were noteworthy biomarker candidates for PCa risk.
Collapse
Affiliation(s)
- Matheus Santos Freire
- Post Graduation Program in Basic and Applied Immunology, Federal University of Amazonas, Manaus, Amazonas, Brazil
| | | | - Tayane Moura Martins
- Medicine College, Altamira University Campus, Federal University of Para, Altamira, PA, Brazil
| | | | - Antonio Carlos Lima
- Medicine College, Altamira University Campus, Federal University of Para, Altamira, PA, Brazil
| | | | - Felipe Rodolfo Pereira da Silva
- Post Graduation Program in Basic and Applied Immunology, Federal University of Amazonas, Manaus, Amazonas, Brazil; Medicine College, Altamira University Campus, Federal University of Para, Altamira, PA, Brazil.
| | | |
Collapse
|
|
2
|
Comert S, Sen S, Eryilmaz O, Doruk C, Ulusan M, Demokan S. Evaluation of genetic and epigenetic changes of Tumor Necrosis Factor-Alpha gene in larynx cancer. Pathol Res Pract 2022; 238:154085. [PMID: 36027653 DOI: 10.1016/j.prp.2022.154085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 08/11/2022] [Accepted: 08/18/2022] [Indexed: 11/11/2022]
Abstract
BACKGROUND Tumor Necrosis Factor-Alpha (TNF-α) is a proinflammatory cytokine that plays a role in inflammation, which is one of the hallmarks of cancer, and its polymorphic variants have been associated with disease risk in many cancers in the literature. The aim of this study was to investigate four different polymorphic variants, differential methylation and expression status of the TNF-α gene and to determine the associations between these variants and disease risk, and to evaluate the relationship between the results and clinical parameters. We purposed to investigate the genetic and epigenetic alterations of the TNF-α gene in larynx cancer (LC). MATERIAL AND METHODS After isolation of DNA/RNA from whole blood, tumor and normal tissue, polymorphic variant alleles differrential expression and methylation levels were analyzed by RFLP, semiquantitative RT-PCR, and restriction enzyme digestion, respectively. TNF-α expression and methylation levels were calculated using BIO1D software. The frequencies of the variants c.-238 G>A (rs361525), c.-857 C>T (rs1799724), c.-863 C>A (rs1800630), and c.-1031 T > C (rs1799964) in the promoter region of TNF-α in LC Turkish patients and healthy individuals were examined using the De-Finetti case-control program. Haplotype frequencies and linkage disequilibrium were analyzed using the SNPStats program. RESULTS The frequency of genotype c.-1031 T > C was significantly lower in patients than in healthy individuals [TT vs TC: OR (%95CI) = 7.00 (1.75-27.93), p = 0.003, χ2 = 8.76]. The heterozygous variant of - 857 was associated with recurrence [T vs G: OR (%95CI) = 0.15 (0.02-0.95), p = 0.02, χ2 = 4.86]. For c.-238 G>A, c.-857 C>T, and c.-863 C>A, there was no statistically significant difference between the patient and healthy group in terms of disease risk. A significant association was found between c.-1031 T > C and disease risk of LC. Decreased expression was detected in 46% (23/50) and increased expression in 54% (27/50) of tumor tissue samples compared to the matched normal tissues of patients. Methylation-related loss of expression was detected in 53.3% (16/30) of patients. CONCLUSION Our study is the first investigating four different polymorphic regions of the TNF-α promoter region and the expression/methylation status of TNF-α in the same LC patient and healthy cohort. According to our results, the c.-1031 T > C variant was reported to be significantly associated with a reduced risk of LC. In addition, the TNF-α variant c. -857 C>T suggests that it may be a potential biomarker for predicting the recurrence of LC. An association between c. -857 C>T variant and methylation-based expression status was observed.
Collapse
Affiliation(s)
- Sevde Comert
- Department of Basic Oncology, Oncology Institute, Istanbul University, Istanbul, Türkiye; Department of Basic Oncology, Institute of Graduate Studies in Health Sciences, Istanbul University, Istanbul, Türkiye
| | - Sena Sen
- Department of Basic Oncology, Oncology Institute, Istanbul University, Istanbul, Türkiye
| | - Onder Eryilmaz
- Department of Basic Oncology, Oncology Institute, Istanbul University, Istanbul, Türkiye
| | - Can Doruk
- Department of Otorhinolaryngology-Head and Neck Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
| | - Murat Ulusan
- Department of Otorhinolaryngology-Head and Neck Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
| | - Semra Demokan
- Department of Basic Oncology, Oncology Institute, Istanbul University, Istanbul, Türkiye.
| |
Collapse
|
|
3
|
Kosałka-Węgiel J, Lichołai S, Dziedzina S, Milewski M, Kuszmiersz P, Rams A, Gąsior J, Matyja-Bednarczyk A, Kwiatkowska H, Korkosz M, Siwiec A, Koźlik P, Padjas A, Sydor W, Dropiński J, Sanak M, Musiał J, Bazan-Socha S. Genetic Association between TNFA Polymorphisms (rs1799964 and rs361525) and Susceptibility to Cancer in Systemic Sclerosis. Life (Basel) 2022; 12:life12050698. [PMID: 35629365 PMCID: PMC9145848 DOI: 10.3390/life12050698] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Revised: 04/29/2022] [Accepted: 05/04/2022] [Indexed: 11/16/2022] Open
Abstract
Tumor necrosis factor (TNF)-α is a proinflammatory cytokine that plays an important role in the pathogenesis of autoimmune diseases. The aim of the study was to establish an association between TNF-α promoter variability and systemic sclerosis (SSc). The study included 43 SSc patients and 74 controls. Four single nucleotide polymorphisms (rs361525, rs1800629, rs1799724, and rs1799964) located at the promoter of the TNFA gene were genotyped using commercially available TaqMan allelic discrimination assays with real-time PCR. The rs1799724 allele was associated with an increased SSc susceptibility (p = 0.028). In turn, none of the polymorphisms studied were related to the clinical and laboratory parameters of SSc patients, except for a higher prevalence of anti-Ro52 antibodies in the AG rs1800629 genotype in comparison to GG carriers (p = 0.04). Three of four cancer patients had both CT rs1799964 and AG rs361525 genotypes; thus, both of them were related to the increased risk of cancer, as compared to the TT (p = 0.03) and GG carriers (p = 0.0003), respectively. The TNFA C rs1799724 variant is associated with an increased risk of SSc, while the CT rs1799964 and AG rs361525 genotypes might enhance cancer susceptibility in SSc patients, although large observational and experimental studies are needed to verify the above hypothesis.
Collapse
Affiliation(s)
- Joanna Kosałka-Węgiel
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
- Rheumatology and Immunology Clinical Department, University Hospital, 30-688 Kraków, Poland;
- Department of Rheumatology and Immunology, Jagiellonian University Medical College, 30-688 Kraków, Poland
- Correspondence: ; Tel.: +48-12-400-31-10
| | - Sabina Lichołai
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
| | - Sylwia Dziedzina
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
| | - Mamert Milewski
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
- Outpatient Clinic for the Immunological and Hypercoagulable Diseases, University Hospital, 30-688 Kraków, Poland
| | - Piotr Kuszmiersz
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
- Rheumatology and Immunology Clinical Department, University Hospital, 30-688 Kraków, Poland;
| | - Anna Rams
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
| | - Jolanta Gąsior
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
| | - Aleksandra Matyja-Bednarczyk
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
- Outpatient Clinic for the Immunological and Hypercoagulable Diseases, University Hospital, 30-688 Kraków, Poland
| | | | - Mariusz Korkosz
- Rheumatology and Immunology Clinical Department, University Hospital, 30-688 Kraków, Poland;
- Department of Rheumatology and Immunology, Jagiellonian University Medical College, 30-688 Kraków, Poland
| | - Andżelika Siwiec
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
- Rheumatology and Immunology Clinical Department, University Hospital, 30-688 Kraków, Poland;
| | - Paweł Koźlik
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
- Department of Hematology, University Hospital, 30-688 Kraków, Poland
| | - Agnieszka Padjas
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
- Outpatient Clinic for the Immunological and Hypercoagulable Diseases, University Hospital, 30-688 Kraków, Poland
| | - Wojciech Sydor
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
- Rheumatology and Immunology Clinical Department, University Hospital, 30-688 Kraków, Poland;
| | - Jerzy Dropiński
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
- Outpatient Clinic for the Immunological and Hypercoagulable Diseases, University Hospital, 30-688 Kraków, Poland
| | - Marek Sanak
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
| | - Jacek Musiał
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
- Outpatient Clinic for the Immunological and Hypercoagulable Diseases, University Hospital, 30-688 Kraków, Poland
| | - Stanisława Bazan-Socha
- Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Poland; (S.L.); (S.D.); (M.M.); (P.K.); (A.R.); (J.G.); (A.M.-B.); (A.S.); (P.K.); (A.P.); (W.S.); (J.D.); (M.S.); (J.M.); (S.B.-S.)
- Outpatient Clinic for the Immunological and Hypercoagulable Diseases, University Hospital, 30-688 Kraków, Poland
| |
Collapse
|